Home ›
NPI 1336464668
NPI deactivated
1336464668
1336464668 was paid $16.28M by Medicaid between Jan 2018 and Dec 2024, across 156 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 46% of everything it billed.
33Billing provider info1336464668
33aNPI1336464668
33bProvider type—
28Total paid$16.28M
24GClaims700,813
24DCodes billed156
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,751 | $432K | |
| 2019 | 29,006 | $599K | |
| 2020 | 92,038 | $2.87M | |
| 2021 | 191,654 | $5.46M | |
| 2022 | 157,818 | $3.59M | |
| 2023 | 144,806 | $2.15M | |
| 2024incomplete | 72,740 | $1.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 46% | 114,854 | 96,493 | $7.50M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 10% | 90,284 | 77,649 | $1.66M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 9.2% | 12,596 | 11,107 | $1.50M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.3% | 6,589 | 6,486 | $697K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.1% | 16,249 | 15,339 | $496K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.1% | 26,480 | 26,268 | $340K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.6% | 6,543 | 5,926 | $254K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.4% | 28,882 | 28,523 | $226K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.4% | 2,867 | 2,778 | $223K |
| 80061 | Lipid panel | 1.1% | 33,820 | 33,497 | $187K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 10,038 | 9,802 | $184K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 2,642 | 2,564 | $183K |
144 more codes
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 9,555 | $176K |
| 80053 | Comprehensive metabolic panel | 1.0% | 33,652 | $164K |
| 87529 | <1% | 4,101 | $157K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 8,895 | $156K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 37,959 | $137K |
| 82607 | <1% | 20,457 | $131K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 30,217 | $130K |
| 86328 | <1% | 3,339 | $114K | |
| 87634 | <1% | 4,268 | $111K | |
| 87481 | <1% | 4,556 | $103K | |
| 80074 | <1% | 4,560 | $93K | |
| 87511 | <1% | 4,607 | $90K | |
| 87563 | <1% | 4,291 | $88K | |
| 87631 | <1% | 1,837 | $85K | |
| 84439 | <1% | 18,351 | $76K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,788 | $68K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,508 | $58K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 684 | $50K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,470 | $46K |
| 82746 | <1% | 5,417 | $36K | |
| 86803 | <1% | 4,778 | $35K | |
| 82728 | <1% | 5,303 | $33K | |
| 84481 | <1% | 4,384 | $31K | |
| 84153 | <1% | 3,694 | $30K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 248 | $28K |
| 82570 | <1% | 5,500 | $26K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,730 | $25K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,583 | $24K |
| 84480 | <1% | 3,802 | $21K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 214 | $20K |
| 87581 | <1% | 1,697 | $18K | |
| 83735 | <1% | 5,784 | $18K | |
| 87486 | <1% | 1,682 | $18K | |
| 83986 | <1% | 377 | $18K | |
| 84311 | <1% | 372 | $17K | |
| 83550 | <1% | 4,331 | $17K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,088 | $17K |
| 86703 | <1% | 3,523 | $16K | |
| 83540 | <1% | 5,170 | $15K | |
| 84403 | <1% | 1,255 | $15K | |
| 87186 | <1% | 1,874 | $15K | |
| 84550 | <1% | 7,498 | $15K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 193 | $14K |
| 87340 | <1% | 2,659 | $14K | |
| 82043 | <1% | 5,615 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,462 | $13K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 456 | $11K |
| 84702 | <1% | 1,333 | $10K | |
| 86696 | <1% | 832 | $9K | |
| 87088 | <1% | 2,116 | $9K | |
| 87077 | <1% | 2,100 | $9K | |
| 86592 | <1% | 4,503 | $9K | |
| 80305 | <1% | 1,265 | $9K | |
| 86317 | <1% | 1,033 | $8K | |
| 87070 | <1% | 1,954 | $7K | |
| 86704 | <1% | 938 | $6K | |
| 85651 | <1% | 3,234 | $6K | |
| 84100 | <1% | 2,875 | $6K | |
| 86695 | <1% | 789 | $6K | |
| 86708 | <1% | 855 | $6K | |
| 82550 | <1% | 1,796 | $5K | |
| 84436 | <1% | 2,399 | $5K | |
| 86038 | <1% | 874 | $5K | |
| 84146 | <1% | 486 | $4K | |
| 80076 | <1% | 1,068 | $4K | |
| 85027 | <1% | 1,266 | $4K | |
| 86480 | <1% | 121 | $4K | |
| 83001 | <1% | 438 | $4K | |
| 81001 | <1% | 3,027 | $4K | |
| 83002 | <1% | 427 | $4K | |
| 87653 | <1% | 211 | $3K | |
| 80164 | <1% | 669 | $3K | |
| 87632 | <1% | 38 | $3K | |
| 86140 | <1% | 1,239 | $3K | |
| 87498 | <1% | 311 | $3K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 276 | $3K |
| 83690 | <1% | 843 | $3K | |
| 86431 | <1% | 908 | $3K | |
| 82670 | <1% | 173 | $2K | |
| 87503 | <1% | 342 | $2K | |
| 86593 | <1% | 1,555 | $2K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 328 | $2K |
| 87640 | <1% | 153 | $2K | |
| 84479 | <1% | 881 | $2K | |
| 83880 | <1% | 130 | $2K | |
| 84460 | <1% | 764 | $2K | |
| 84450 | <1% | 765 | $2K | |
| 82150 | <1% | 618 | $2K | |
| 86701 | <1% | 280 | $2K | |
| 85610 | <1% | 875 | $2K | |
| 82977 | <1% | 455 | $2K | |
| 86141 | <1% | 200 | $1K | |
| 81003 | <1% | 1,141 | $1K | |
| 87150 | <1% | 26 | $1K | |
| 82947 | <1% | 526 | $1K | |
| 86304 | <1% | 103 | $1K | |
| 86301 | <1% | 100 | $1K | |
| 82248 | <1% | 421 | $984.03 | |
| 84402 | <1% | 141 | $973.79 | |
| 81000 | <1% | 499 | $965.16 | |
| 84520 | <1% | 539 | $957.96 | |
| 82040 | <1% | 454 | $933.81 | |
| 82565 | <1% | 347 | $906.69 | |
| 82950 | <1% | 863 | $807.05 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 20 | $689.08 |
| 80051 | <1% | 209 | $678.66 | |
| 83615 | <1% | 275 | $639.45 | |
| 84410 | <1% | 35 | $564.69 | |
| 87500 | <1% | 22 | $561.68 | |
| 86762 | <1% | 48 | $541.85 | |
| 86430 | <1% | 270 | $493.63 | |
| 84154 | <1% | 76 | $465.99 | |
| 83013 | <1% | 56 | $446.18 | |
| 85730 | <1% | 157 | $430.70 | |
| 85007 | <1% | 342 | $415.56 | |
| 86706 | <1% | 77 | $367.71 | |
| 80178 | <1% | 112 | $344.96 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 1,003 | $337.50 |
| 82540 | <1% | 190 | $304.73 | |
| 83655 | <1% | 69 | $292.79 | |
| 83090 | <1% | 57 | $268.81 | |
| 87641 | <1% | 22 | $225.29 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 15 | $220.78 |
| 86705 | <1% | 217 | $214.44 | |
| 86677 | <1% | 27 | $175.92 | |
| 81015 | <1% | 470 | $168.59 | |
| 84703 | <1% | 61 | $149.42 | |
| 82465 | <1% | 49 | $130.76 | |
| 82553 | <1% | 26 | $107.20 | |
| 83721 | <1% | 15 | $105.18 | |
| 82378 | <1% | 12 | $97.34 | |
| 84295 | <1% | 35 | $94.45 | |
| 84132 | <1% | 35 | $93.56 | |
| 83718 | <1% | 17 | $88.08 | |
| 84478 | <1% | 18 | $65.72 | |
| 82374 | <1% | 15 | $48.45 | |
| 82435 | <1% | 15 | $45.75 | |
| 82310 | <1% | 13 | $23.92 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 299 | $10.00 |
| 86709 | <1% | 175 | $8.19 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 149 | $0.00 |
| 84270 | 0% | 227 | $0.00 | |
| 80050 | General health panel | 0% | 335 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.